XML 33 R22.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On October 2, 2018, the Company sold to Qpex certain pre-clinical infectious disease assets not acquired by Melinta for approximately $2.7 million in upfront consideration and up to $29 million upon the achievement of certain milestones related to the pre-clinical assets. The related assets and liabilities sold to Qpex are presented as “Current assets held for sale” and “Current liabilities held for sale” on the accompanying consolidated balance sheets as of September 30, 2018.